2014
Gastroenterologists’ Practice Patterns for Positive Fecal Occult Blood Test
Kim JJ, Han A, Yan AW, Cao D, Laine L. Gastroenterologists’ Practice Patterns for Positive Fecal Occult Blood Test. Journal Of Clinical Gastroenterology 2014, 48: 119-126. PMID: 23632353, DOI: 10.1097/mcg.0b013e31828f1c8d.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdultAnemia, Iron-DeficiencyColonoscopyDyspepsiaEndoscopy, GastrointestinalFemaleGastroenterologyHeartburnHumansInstitutional PracticeLaryngopharyngeal RefluxMaleMalpracticeMiddle AgedOccult BloodPractice Patterns, Physicians'Private PracticeProfessional Practice LocationTime FactorsConceptsPositive fecal occult blood testFecal occult blood testUpper GI symptomsOccult blood testGI symptomsBlood testsFear of litigationThird of gastroenterologistsColorectal cancer screeningPrivate practiceAdults 50 yearsIron deficiency anemiaDifferent daysGastrointestinal symptomsCancer screeningPractice patternsEsophagogastroduodenoscopyColonoscopyPotential respondersMultivariate analysisAnemiaFurther evaluationSymptomsSame dayPatients
2010
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies. Alimentary Pharmacology & Therapeutics 2010, 33: 203-212. PMID: 21114792, DOI: 10.1111/j.1365-2036.2010.04516.x.Peer-Reviewed Original ResearchConceptsHeartburn resolutionErosive oesophagitisExtended releaseLA grade CSevere erosive oesophagitisDouble-blind trialDouble-blind studyPossibility of benefitCurrent PPIsD oesophagitisSevere oesophagitisGERD patientsSecondary endpointsPrimary endpointSymptomatic resolutionAcid suppressionSubgroup analysisDrug exposureClinical trialsOesophagitisGrade DGrade CFurther evaluationEsomeprazoleAcid inhibition